178 MEDICIS-PROMED: MEDICIS-Produced Radioisotope Beams for Medicine an Innovative Training Networ  by Viertl, D. et al.
ICTR-PHE 2016  S87 
 
[1] Smeets, J.; Roellinghoff, F.; Prieels, D.; Stichelbaut, F.; 
Benilov, A.; Busca, P.; Fiorini, C.; Peloso, R.; Basilavecchia, 
M.; Frizzi, T.; Dehaes, J. & Dubus, A.: Prompt gamma 
imaging with a slit camera for real-time range control in 
proton therapy. Phys. Med. Biol., 2012, 57, 3371-3405 
[2] Perali, I.; Celani, A.; Bombelli, L.; Fiorini, C.; Camera, F.; 
Clementel, E.; Henrotin, S.; Janssens, G.; Prieels, D.; 
Roellinghoff, F.; Smeets, J.; Stichelbaut, F. & Stappen, F. V.: 
Prompt gamma imaging of proton pencil beams at clinical 
dose rate. Phys. Med. Biol., 2014, 59, 5849-5871 
[3] Priegnitz, M.; Helmbrecht, S.; Janssens, G.; Perali, I.; 
Smeets, J.; Stappen, F. V.; Sterpin, E. & Fiedler, F.: 
Measurement of prompt gamma profiles in inhomogeneous 
targets with a knife-edge slit camera during proton 
irradiation. Phys. Med. Biol., 2015, 60, 4849-4871 
 
178 
MEDICIS-PROMED: MEDICIS-Produced Radioisotope Beams 
for Medicine an Innovative Training Network  
D. Viertl1,2, F. Buchegger2, J. O. Prior2, Ph. Morel1, O. Ratib1, 
L. Bühler1, Th. Stora3, CERN-MEDICIS collaboration4  
1Hôpitaux Universitaires de Genève, Gabrielle-Perret-Gentil 
4, 1205 Genève 
2Lausanne University Hospital, Rue du Bugnon 46, 1011 
Lausanne  
3Organisation Européenne pour la recherche nucléaire 
(CERN), Route de Meyrin 385, 1217 Meyrin 
4C2TN (Centro de Ciências e Tecnologias Nucleares, 
Lisbonne), CERN (Meyrin), CHUV (Lausanne), HUG (Genève), 
ISOLDE (Meyrin), ISREC-EPFL (Ecublens), KUL (Katholieke 
Universiteit Leuven), SINP (Saha Institute of Nuclear Physics 
India), Nuclear Medicine Sofia (Bulgaria). 
 
MEDICIS-PROMED aims to develop a network of academic, 
medical and industrial partners providing an extensive 
doctoral program to 15 young scientists in the field of new 
personalized treatments using radioisotope beams, notably 
for treatment of ovarian cancer. 
This field is expected to expand rapidly and provide new 
types of treatments combining imaging and personalized 
treatment with the same radiopharmaceutical and different 
types of isotopes, emitting positron or gamma light for 
imaging on one side, and Auger electron, beta and alpha 
radiation for treatment on the other side, known as 
theranostics pairs [1]. In addition, positron emitting isotopes 
such as 11Carbon can personalize hadron therapy treatments 
by imaging the dose distribution of the implanted ions [2,3]. 
In this scheme, CERN, the European Organization for Nuclear 
Research is the coordinating partner, and collaborates with 
local hospitals which are able to exploit short-lived isotopes 
produced in the newly constructed CERN-MEDICIS facility. It 
also fits within an extended network of high-technology 
companies and leading academic research institutes, which 
will design new components for the development or tests of 
innovative radiopharmaceuticals and imaging agents for 
personalized treatment. It brings world-class researchers 
together in the field of lasers and isotope mass separation, 
accelerators, material science, oncology, entrepreneurial 
radiopharmaceutical production, and imaging, to propose 
new solutions to the second deadliest cancer for women. 
The program will develop along three R&D work packages 
integrating multidisciplinary intersectorial training teams: 
• Development of new radioisotopes and techniques using 
isotope mass separation for medicine and based on CERN-
MEDICIS. 
• Development and test of 11Carbon PET-aided hadron 
therapy. 
• Synthesis & tests of radiopharmaceuticals to diagnose and 
treat ovarian cancer. 
Because of the unique capability of CERN-MEDICIS to produce 
medical batches of innovative isotopes, such as 149Terbium 
[4] and thanks and to the new generation of young scientists 
that will be trained in the relevant fields the MEDICIS-
PROMED innovative training network will significantly 
advance the use of radioisotopes for personalized medicine in 
Europe and go beyond the present common practices. 
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Purpose: Experimental data for the impact of fractionated 
proton beam exposures is limited. Using acute exposures, the 
current clinical adoption of a generic, constant cell killing 
RBE has been shown to underestimate the effect of the sharp 
increase in Linear Energy Transfer (LET) in the distal regions 
of the spread-out Bragg peak (SOBP).  Here we aim to 
investigate the clinical implications of a variable Relative 
Biological Effectiveness (RBE) on proton dose fractionation.  
Methods and Materials: Human fibroblasts (AG01522) were 
irradiated with 219.65 MeV protons at four depth positions 
along a clinical SOBP. These were delivered as fractionated 
regimes with an inter-fraction period of 24 hours at the 
Prague Proton Therapy Centre.  Cell killing RBE variations 
were measured using standard clonogenic assays and were 
further validated using Monte Carlo simulations and 
parameterized using a Linear-Quadratic formalism. 
Results: Consistent with previous studies of a single fraction 
response for both survival and DNA damage (DSB foci) (1,2), 
significant variations in the cell killing RBE for fractionated 
exposures along the proton dose profile were observed.  The 
RBE increased sharply towards the distal position, 
corresponding to a reduction in the cell sparing effectiveness 
of fractionated proton exposures at lower energies and 
higher LET.  The effect is more pronounced at smaller doses 
per fraction. Experimental survival fractions were adequately 
predicted using a Linear Quadratic formalism assuming full 
repair between fractions.  The data were also used to 
validate a parameterized variable RBE model based on linear 
alpha parameter response with LET that showed considerable 
deviations from clinically predicted isoeffective fractionation 
regimes. 
Conclusions: The biologically effective dose calculated using 
the clinically adopted generic RBE of 1.1 significantly 
underestimates the biological effective dose from variable 
RBE for single and fractionated regimes with low doses per 
fraction.  Coupled with an increase in effective range in 
fractionated exposures, the study indicates the needs for the 
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